Citations (52)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Alena Laschtowitz, Christoph Roderburg, Frank Tacke & Raphael Mohr. (2023) Preoperative Immunotherapy in Hepatocellular Carcinoma: Current State of the Art. Journal of Hepatocellular Carcinoma 10, pages 181-191.
Read now
Read now
Lilit Karapetyan, Jason J Luke & Diwakar Davar. (2020) Toll-Like Receptor 9 Agonists in Cancer. OncoTargets and Therapy 13, pages 10039-10060.
Read now
Read now
Articles from other publishers (50)
Xiaoqin Yin, Jian Li, Bei Chen, Kehuang Liu & Shuo Hu. (2023) The predictive value of 18F-FDG PET/CT combined with inflammatory index for major pathological reactions in resectable NSCLC receiving neoadjuvant immunochemotherapy. Lung Cancer 186, pages 107389.
Crossref
Crossref
Baihua Zhang, Xiaotong Guo, Ran Jia, Zhan Wang, Jie Wu, Xiaoyan Chen, Jigang Li, Desong Yang, Xu Li, Wenxiang Wang & Qin Xiao. (2023) Neoadjuvant chemoimmunotherapy cycle number selection for non-small cell lung cancer and clinical outcomes: a real-world analysis. Frontiers in Oncology 13.
Crossref
Crossref
Shitao Jiang, Yaoge Liu, Han Zheng, Lei Zhang, Haitao Zhao, Xinting Sang, Yiyao Xu & Xin Lu. (2023) Evolutionary patterns and research frontiers in neoadjuvant immunotherapy: a bibliometric analysis. International Journal of Surgery 109:9, pages 2774-2783.
Crossref
Crossref
Emma Boydell, Jose L. Sandoval, Olivier Michielin, Michel Obeid, Alfredo Addeo & Alex Friedlaender. (2023) Neoadjuvant Immunotherapy: A Promising New Standard of Care. International Journal of Molecular Sciences 24:14, pages 11849.
Crossref
Crossref
Aswathy R. Devan, Bhagyalakshmi Nair, Manu Kanjoormana Aryan, Vijayastelar B. Liju, Joel Joy Koshy, Bijo Mathew, Arun Valsan, Hoon Kim & Lekshmi R. Nath. (2023) Decoding Immune Signature to Detect the Risk for Early-Stage HCC Recurrence. Cancers 15:10, pages 2729.
Crossref
Crossref
Tianyun Qiao, Jinbo Zhao, Xiangbing Xin, Yanlu Xiong, Wenwen Guo, Fancheng Meng, Hui Li, Yangbo Feng, Hui Xu, Changhong Shi & Yong Han. (2022) Combined pembrolizumab and bevacizumab therapy effectively inhibits non-small-cell lung cancer growth and prevents postoperative recurrence and metastasis in humanized mouse model. Cancer Immunology, Immunotherapy 72:5, pages 1169-1181.
Crossref
Crossref
J.M. Versluis, A.M. Menzies, K. Sikorska, E.A. Rozeman, R.P.M. Saw, W.J. van Houdt, H. Eriksson, W.M.C. Klop, S. Ch’ng, J.V. van Thienen, H. Mallo, M. Gonzalez, A. Torres Acosta, L.G. Grijpink-Ongering, A. van der Wal, A. Bruining, B.A. van de Wiel, R.A. Scolyer, J.B.A.G. Haanen, T.N. Schumacher, A.C.J. van Akkooi, G.V. Long & C.U. Blank. (2023) Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials. Annals of Oncology 34:4, pages 420-430.
Crossref
Crossref
Davide Mangani, Dandan Yang & Ana C. Anderson. (2023) Learning from the nexus of autoimmunity and cancer. Immunity 56:2, pages 256-271.
Crossref
Crossref
Yurong Peng, Zhuo Li, Yucheng Fu, Yue Pan, Yue Zeng, Junqi Liu, Chaoyue Xiao, Yingzhe Zhang, Yahui Su, Guoqing Li & Fang Wu. (2023) Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer. Frontiers in Oncology 13.
Crossref
Crossref
Min Fang, Qingqing Hang, Haitao Jiang, Lei Cai, Jinlin Hu, Hangjie Ying, Qing Gu, Xiaofu Yu, Jinshi Liu & Xiaojing Lai. (2023) Efficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable non–small cell lung cancer in real world. Frontiers in Oncology 12.
Crossref
Crossref
Yurong Peng, Zhuo Li, Yucheng Fu, Yue Pan, Yue Zeng, Junqi Liu, Chaoyue Xiao, Yingzhe Zhang, Yahui Su, Guoqing Li & Fang Wu. (2023) Avances y perspectivas de la inmunoterapia perioperatoria en el cáncer de pulmón no-microcítico. Kompass Neumología 5:2, pages 47-58.
Crossref
Crossref
Qing Li, Ting Liu & Zhenyu Ding. (2022) Neoadjuvant immunotherapy for resectable esophageal cancer: A review. Frontiers in Immunology 13.
Crossref
Crossref
Giuseppe Viscardi, Fabiana Vitiello, Alberto Servetto, Valerio Gristina, Elio Gregory Pizzutilo, Maria Anna Canciello, Paola Maria Medusa, Fabio Salomone, Gaetano Di Guida, Mariano Mollica, Luigi Aronne, Roberto Scaramuzzi, Filomena Napolitano, Ciro Battiloro, Francesca Caputo, Marina Gilli, Giuseppe Totaro, Carlo Curcio, Danilo Rocco & Vincenzo Montesarchio. (2022) Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review. Cancers 14:23, pages 5810.
Crossref
Crossref
Branka Petricevic, Julijan Kabiljo, Rebecca Zirnbauer, Henning Walczak, Johannes Laengle & Michael Bergmann. (2022) Neoadjuvant immunotherapy in gastrointestinal cancers – The new standard of care?. Seminars in Cancer Biology 86, pages 834-850.
Crossref
Crossref
Manuel Olmos, Rainer Lutz, Tjark-Ole Büntemeyer, Jacek Glajzer, Christopher-Philipp Nobis, Jutta Ries, Tobias Möst, Markus Eckstein, Markus Hecht, Antoniu-Oreste Gostian, Michael Erdmann, Yannick Foerster, Marco Kesting & Manuel Weber. (2022) Case report: Patient specific combination of surgery and immunotherapy in advanced squamous cell carcinoma of the head and neck – a case series and review of literature. Frontiers in Immunology 13.
Crossref
Crossref
He Wang, Sihan Li, Tingting Liu, Jun Chen & Jun Dang. (2022) Neoadjuvant immune checkpoint inhibitor in combination with chemotherapy or chemoradiotherapy in resectable esophageal cancer: A systematic review and meta-analysis. Frontiers in Immunology 13.
Crossref
Crossref
Jiawei Chen, Hongsheng Deng, Jiaxi He, Zhufeng Wang & Shuben Li. (2022) Impact of the interval between neoadjuvant immunochemotherapy and surgery on surgical–pathological outcomes in non-small cell lung cancer. Frontiers in Oncology 12.
Crossref
Crossref
Ioannis A. Vathiotis, Jennifer M. Johnson, Adam Luginbuhl, David Cognetti, Joseph Curry & Athanassios Argiris. (2022) Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches. Cancer Treatment Reviews 109, pages 102437.
Crossref
Crossref
Pablo Nenclares, Antonio Rullan, Kenric Tam, Lara A. Dunn, Maie St. John & Kevin J. Harrington. (2022) Introducing Checkpoint Inhibitors Into the Curative Setting of Head and Neck Cancers: Lessons Learned, Future Considerations. American Society of Clinical Oncology Educational Book:42, pages 511-526.
Crossref
Crossref
Miguel F. Sanmamed, Pedro Berraondo, Maria E. Rodriguez-Ruiz & Ignacio Melero. (2022) Charting roadmaps towards novel and safe synergistic immunotherapy combinations. Nature Cancer 3:6, pages 665-680.
Crossref
Crossref
Hongtao Duan, Changjian Shao, Minghong Pan, Honggang Liu, Xiaoping Dong, Yong Zhang, Liping Tong, Yingtong Feng, Yuanyuan Wang, Lu Wang, Neil B. Newman, Inderpal S. Sarkaria, John V. Reynolds, Francesco De Cobelli, Zhiqiang Ma, Tao Jiang & Xiaolong Yan. (2022) Neoadjuvant Pembrolizumab and Chemotherapy in Resectable Esophageal Cancer: An Open-Label, Single-Arm Study (PEN-ICE). Frontiers in Immunology 13.
Crossref
Crossref
Friedrich Foerster, Simon Johannes Gairing, Sumera Irie Ilyas & Peter Robert Galle. (2022) Emerging immunotherapy for HCC: A guide for hepatologists. Hepatology 75:6, pages 1604-1626.
Crossref
Crossref
Fajiu Li, Ying Chen, Juanjuan Wu, Chenghong Li, Shi Chen, Ziyang Zhu, Wei Qin, Min Liu, Bingzhu Hu, Shuang Liu & Wenzhao Zhong. (2022) The earlier, the better? A review of neoadjuvant immunotherapy in resectable non‐small‐cell lung cancer. Chronic Diseases and Translational Medicine 8:2, pages 100-111.
Crossref
Crossref
Ann Marie Egloff & Ravindra Uppaluri. (2022) Preoperative immunotherapy for head and neck cancers: state of art. Current Opinion in Oncology 34:3, pages 185-195.
Crossref
Crossref
Paulien Kaptein, Celia Jacoberger-Foissac, Petros Dimitriadis, Paula Voabil, Marjolein de Bruijn, Simone Brokamp, Irene ReijersJudith Versluis, Gahyathiri NallanHannah Triscott, Elizabeth McDonald, Joshua Tay, Georgina V. Long, Christian U. BlankDaniela S. Thommen & Michele W.L. Teng. (2022) Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors. Science Translational Medicine 14:642.
Crossref
Crossref
Wan Xing HongIdit Sagiv-Barfi, Debra K. CzerwinskiAdrienne Sallets & Ronald Levy. (2022) Neoadjuvant Intratumoral Immunotherapy with TLR9 Activation and Anti-OX40 Antibody Eradicates Metastatic Cancer. Cancer Research 82:7, pages 1396-1408.
Crossref
Crossref
Xintao Cui, Jiesheng Rong & Chunlei Cong. (2022) Ovalbumin loaded CuS nanoparticle for tumour modulation and enhanced immunotherapy of osteosarcoma. Micro & Nano Letters 17:5, pages 101-106.
Crossref
Crossref
Wenting Li & Shiying Yu. (2022) Research progress on immune checkpoint inhibitors in neoadjuvant therapy for gastric cancer. Oncology and Translational Medicine 8:2, pages 74-82.
Crossref
Crossref
Thomas U Marron, Maria Isabel Fiel, Pauline Hamon, Nathalie Fiaschi, Edward Kim, Stephen C Ward, Zhen Zhao, Joel Kim, Paul Kennedy, Ganesh Gunasekaran, Parissa Tabrizian, Deborah Doroshow, Meredith Legg, Ashley Hammad, Assaf Magen, Alice O Kamphorst, Muhammed Shareef, Namita T Gupta, Raquel Deering, Wei Wang, Fang Wang, Pradeep Thanigaimani, Jayakumar Mani, Leanna Troncoso, Alexandra Tabachnikova, Christie Chang, Guray Akturk, Mark Buckup, Steven Hamel, Giorgio Ioannou, Clotilde Hennequin, Hajra Jamal, Haley Brown, Antoinette Bonaccorso, Daniel Labow, Umut Sarpel, Talia Rosenbloom, Max W Sung, Baijun Kou, Siyu Li, Vladimir Jankovic, Nicola James, Sara C Hamon, Hung Kam Cheung, Jennifer S Sims, Elizabeth Miller, Nina Bhardwaj, Gavin Thurston, Israel Lowy, Sacha Gnjatic, Bachir Taouli, Myron E Schwartz & Miriam Merad. (2022) Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. The Lancet Gastroenterology & Hepatology 7:3, pages 219-229.
Crossref
Crossref
Prabhani U. Atukorale, Taylor J. Moon, Alexandr R. Bokatch, Christina F. Lusi, Jackson T. Routhier, Victoria J. Deng & Efstathios Karathanasis. (2022) Dual agonist immunostimulatory nanoparticles combine with PD1 blockade for curative neoadjuvant immunotherapy of aggressive cancers. Nanoscale 14:4, pages 1144-1159.
Crossref
Crossref
Taylor J Aiken, David Komjathy, Matthew Rodriguez, Ashley Stuckwisch, Arika Feils, Vladimir Subbotin, Jen Birstler, Stephen D Gillies, Alexander L Rakhmilevich, Amy K Erbe & Paul M Sondel. (2022) Short-course neoadjuvant in situ vaccination for murine melanoma. Journal for ImmunoTherapy of Cancer 10:1, pages e003586.
Crossref
Crossref
Joris L. Vos, Joris B. W. Elbers, Oscar Krijgsman, Joleen J. H. Traets, Xiaohang Qiao, Anne M. van der Leun, Yoni Lubeck, Iris M. Seignette, Laura A. Smit, Stefan M. Willems, Michiel W. M. van den Brekel, Richard Dirven, M. Baris Karakullukcu, Luc Karssemakers, W. Martin C. Klop, Peter J. F. M. Lohuis, Willem H. Schreuder, Ludi E. Smeele, Lilly-Ann van der Velden, I. Bing Tan, Suzanne Onderwater, Bas Jasperse, Wouter V. Vogel, Abrahim Al-Mamgani, Astrid Keijser, Vincent van der Noort, Annegien Broeks, Erik Hooijberg, Daniel S. Peeper, Ton N. Schumacher, Christian U. Blank, Jan Paul de Boer, John B. A. G. Haanen & Charlotte L. Zuur. (2021) Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma. Nature Communications 12:1.
Crossref
Crossref
Wenwen Zhang, Bingyang Hu, Jun Han, Zhanbo Wang, Guangyu Ma, Huiyi Ye, Jing Yuan, Junning Cao, Ze Zhang, Jihang Shi, Mingyi Chen, Xun Wang, Yinzhe Xu, Yanshuang Cheng, Lantian Tian, Hongguang Wang & Shichun Lu. (2021) Surgery After Conversion Therapy With PD-1 Inhibitors Plus Tyrosine Kinase Inhibitors Are Effective and Safe for Advanced Hepatocellular Carcinoma: A Pilot Study of Ten Patients. Frontiers in Oncology 11.
Crossref
Crossref
Hirofumi Shibata, Shin Saito & Ravindra Uppaluri. (2021) Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy. Frontiers in Oncology 11.
Crossref
Crossref
Mithunah Krishnamoorthy, John G Lenehan & Saman Maleki Vareki. (2021) Neoadjuvant Immunotherapy for High-Risk, Resectable Malignancies: Scientific Rationale and Clinical Challenges. JNCI: Journal of the National Cancer Institute 113:7, pages 823-832.
Crossref
Crossref
David J. Pinato, Petros Fessas, Gonzalo Sapisochin & Thomas U. Marron. (2021) Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma. Hepatology 74:1, pages 483-490.
Crossref
Crossref
Lorenzo Galluzzi & Abhishek D. Garg. (2021) Immunology of Cell Death in Cancer Immunotherapy. Cells 10:5, pages 1208.
Crossref
Crossref
Anil C. Anand & Subrat K. Acharya. (2021) New Developments in the Treatment of Hepatocellular Carcinoma: The Concept of Adjuvant and Neoadjuvant Chemotherapy. Journal of Clinical and Experimental Hepatology 11:3, pages 284-287.
Crossref
Crossref
Minsu Kwon, Hanul Jung, Gi-Hoon Nam & In-San Kim. (2021) The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy. Journal of Controlled Release 331, pages 321-334.
Crossref
Crossref
Olivia Le Saux, Yasmine Lounici, Pauline Wajda, Sarah Barrin, Christophe Caux, Bertrand Dubois & Isabelle Ray-Coquard. (2021) Neoadjuvant immune checkpoint inhibitors in cancer, current state of the art. Critical Reviews in Oncology/Hematology 157, pages 103172.
Crossref
Crossref
Xabier Mielgo-Rubio, Virginia Calvo, Javier Luna, Jordi Remon, Margarita Martín, Pedro Berraondo, José Ramón Jarabo, Oliver Higuera, Esther Conde, Javier De Castro, Mariano Provencio, Florentino Hernando Trancho, Fernando López-Ríos & Felipe Couñago. (2020) Immunotherapy Moves to the Early-Stage Setting in Non-Small Cell Lung Cancer: Emerging Evidence and the Role of Biomarkers. Cancers 12:11, pages 3459.
Crossref
Crossref
Augustin Le Naour, Adrien Rossary & Marie‐Paule Vasson. (2020) EO771, is it a well‐characterized cell line for mouse mammary cancer model? Limit and uncertainty. Cancer Medicine 9:21, pages 8074-8085.
Crossref
Crossref
Ravindra Uppaluri, Katie M. Campbell, Ann Marie Egloff, Paul Zolkind, Zachary L. Skidmore, Brian Nussenbaum, Randal C. Paniello, Jason T. Rich, Ryan Jackson, Patrik Pipkorn, Loren S. Michel, Jessica Ley, Peter Oppelt, Gavin P. Dunn, Erica K. Barnell, Nicholas C. Spies, Tianxiang Lin, Tiantian Li, David T. Mulder, Youstina Hanna, Iulia Cirlan, Trevor J. Pugh, Tenny Mudianto, Rachel Riley, Liye Zhou, Vickie Y. Jo, Matthew D. Stachler, Glenn J. Hanna, Jason Kass, Robert Haddad, Jonathan D. Schoenfeld, Evisa Gjini, Ana Lako, Wade Thorstad, Hiram A. Gay, Mackenzie Daly, Scott J. Rodig, Ian S. Hagemann, Dorina Kallogjeri, Jay F. Piccirillo, Rebecca D. Chernock, Malachi Griffith, Obi L. Griffith & Douglas R. Adkins. (2020) Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. Clinical Cancer Research 26:19, pages 5140-5152.
Crossref
Crossref
Zhening Zhang, Siyuan Cheng, Jifang Gong, Ming Lu, Jun Zhou, Xiaotian Zhang, Jian Li, Lin Shen & Zhi Peng. (2020) Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series. European Journal of Surgical Oncology 46:10, pages e33-e39.
Crossref
Crossref
Zahra R. Kelly, Vikram C. Gorantla & Diwakar Davar. (2020) The Role of Neoadjuvant Therapy in Melanoma. Current Oncology Reports 22:8.
Crossref
Crossref
Mariacarmela Santarpia, Andrés Aguilar, Imane Chaib, Andrés Felipe Cardona, Sara Fancelli, Fernando Laguia, Jillian Wilhelmina Paulina Bracht, Peng Cao, Miguel Angel Molina-Vila, Niki Karachaliou & Rafael Rosell. (2020) Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies. Cancers 12:6, pages 1475.
Crossref
Crossref
Judith M. Versluis, Georgina V. Long & Christian U. Blank. (2020) Learning from clinical trials of neoadjuvant checkpoint blockade. Nature Medicine 26:4, pages 475-484.
Crossref
Crossref
Juming Yan, Xian-Yang Li, Amelia Roman Aguilera, Christos Xiao, Celia Jacoberger-Foissac, Bianca Nowlan, Simon C. Robson, Courtney Beers, Achim K. Moesta, Nishamol Geetha, Michele W.L. Teng & Mark J. Smyth. (2020) Control of Metastases via Myeloid CD39 and NK Cell Effector Function. Cancer Immunology Research 8:3, pages 356-367.
Crossref
Crossref
Suzanne L. Topalian, Janis M. TaubeDrew M. Pardoll. (2020) Neoadjuvant checkpoint blockade for cancer immunotherapy. Science 367:6477.
Crossref
Crossref
Jake S. O'Donnell, Esmée P. Hoefsmit, Mark J. Smyth, Christian U. Blank & Michele W.L. Teng. (2019) The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment. Clinical Cancer Research 25:19, pages 5743-5751.
Crossref
Crossref